Siga Technologies INC Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Siga Technologies INC (SIGA) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of -$1.13 million as of 2015-12-31, per its 10-K filed 2016-03-04.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2016-03-04
- 2015-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs -$1.13M.
- 2014-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs -$1.61M.
- 2013-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs -$2.28M.
- 2012-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs -$2.95M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2015-12-31 | -$1.13M 10-K · filed 2016-03-04 |
| 2014-12-31 | -$1.61M 10-K · filed 2016-03-04 |
| 2013-12-31 | -$2.28M 10-K · filed 2015-03-06 |
| 2012-12-31 | -$2.95M 10-K · filed 2014-03-10 |
| 2011-12-31 | -$3.67M 10-K/A · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |